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Abstract
Microglia cells are the brain counterpart of macrophages and function as the first defense in the brain. Although
they are neuroprotective in the young brain, microglia cells may be primed to react abnormally to stimuli in the
aged brain and to become neurotoxic and destructive during neurodegeneration. Aging-induced immune senes-
cence occurs in the brain as age-associated microglia senescence, which renders microglia to function abnormally
and may eventually promote neurodegeneration. Microglia senescence is manifested by both morphological
changes and alterations in immunophenotypic expression and inflammatory profile. These changes are likely
caused by microinvironmental factors, but intrinsic factors cannot yet be completely excluded. Microglia senes-
cence appears to underlie the switching of microglia from neuroprotective in the young brain to neurotoxic in the
aged brain. The hypothesis of microglia senescence during aging offers a novel perspective on their roles in aging-
related neurodegeneration. In Parkinson’s disease and Alzheimer’s disease, over-activation of microglia may play an
active role in the pathogenesis because microglia senescence primes them to be neurotoxic during the develop-
ment of the diseases.
Introduction
Microglia are the representative of immune cells in the
relatively immune-privileged central nervous system
(CNS) and account for 10% of the total glial cell popula-
tion in the brain. The initial investigation of microglia
came from Rio-Hortega early in the last century, who
described microglia as a unique cell type in the CNS
with an elongated soma bearing processes extending
from both poles of the cell. When severe brain injury
happens, microglia cells change their morphology dra-
matically, migrate to the lesion sites, and proliferate.
Proliferated microglia cells phagocytose dying cells and
other debris and/or release cytokines to maintain the
microenvironment homeostasis and support injured
neurons, and thus are beneficial for the neuronal survi-
val. However, in the past decades mounting evidence
has also implicated neurotoxic roles of microglia when
over-activated in severe injury or neurodegenerative dis-
eases. Hypotheses trying to explain this double-edged
feature of microglia have been proposed. Here, we
review the senescence-related changes of microglia and
focus on their relevance to neurodegeneration.
Immunosenescence of macrophage lineage
Like macrophages in the periphery, microglia belong to
macrophage lineage and are the first and main form of
active immune defense in the CNS. Aging of the
immune system (immunosenescence) describes a state
of profound age-associated changes in the immune sys-
tem, which contributes to the increased susceptibility to
infection of the elderly[1,2]. Although the compromise
of adaptive immunity mediated by T and B lymphocytes
has gained a significant amount of attention [3-5], the
innate system also experiences significant changes with
advanced age[2]. As the bridge between adaptive and
innate immune system, the aging-associated deteriora-
tion of macrophage lineage is of significance. Although
not universally consistent, accumulating evidence has
demonstrated alterations in macrophage functions in
advanced age. In rodents, the cytokine production
(interleukin 1 (IL-1), tumor necrosis factor (TNF-a))
[6-9] as well as oxidative radicals and iNOS expression
[9] were reported to decline in macrophages with aging.
However, most literature suggests elevated circulating
levels of proinflammatory cytokines[10], which are
believed to be produced mainly by macrophages during
aging. Apparently contradictory results are also seen
regarding receptor expression in macrophages. Renshaw
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expression in macrophages with advanced age[11], while
Boehmer et al [12]. reported that TLR expression was
not affected by age. As macrophages in the periphery, it
is reasonable to believe that microglial alterations play
crucial roles in increased inflammation in the CNS dur-
ing aging and in neurodegeneration.
Microglia activation in the aged brain
It has been proposed that aberrant inflammatory
responses play a role in the etiology of several neurode-
generative diseases, such as Parkinson’s disease (PD) or
Alzheimer’s disease (AD)[13,14], in which aging is the
most important risk factor. Many studies have demon-
strated coexisting neuro-inflammation and neurodegen-
eration[15,16]. The CNS is relatively immune-privileged,
in which the activity of adaptive immunity mediated by
lymphocytes is scarce[17]. On the other hand, major
histocompatibility complex (MHC) antigen, T- and B-
lymphocyte markers, and other immune-cell antigens
can be detected on microglia. Thus, microglia has been
considered to represent the brain’s internal immune sys-
tem. It is speculated that any changes in microglial
activities during aging are key components in influen-
cing the pathogenesis of neurodegeneration.
Microglia normally keep in a quiescent state when not
challenged, and they are thus called resting microglia,
with ramified morphology and weak expression of func-
tion-associated antigens. When triggered by appropriate
stimulation, microglia rapidly transformed from a rest-
ing state to an activated state with deramified shape and
enhanced antigen presentation, which has been graded
to a series of stages[18]. As an active sensor and moni-
tor in the brain, microglia are neuroprotective. However,
uncontrolled microglia response may be dangerous to
the survival of injured neurons or even cause damage to
healthy neurons that are afflicted by excessive inflamma-
tion. Microglia activation is normally controlled under
physiological conditions of the CNS through neuron-glia
contact, CD200R-CD200 pathway[19], neuronal electri-
cal activity[20], and/or some soluble neurotransmitters
[21]. Despite this microglia-quiescence mechanisms,
increased microglia activati o ni nt h eh e a l t h ya g e db r a i n
has been reported in diverse mammalian species, such
human[22], monkey[23,24] and rat[25]. During normal
aging of the monkey brain, microglial expression of
MHC class II increases with age[23], and the phagocytic
activity of microglia increases age-dependently, leading
to electron dense inclusions that have the appearance of
myelin in microglia[24]. Immunohistochemical studies
by using activated microglia marker OX-6 staining also
found microglial activation with age-related changes[25].
Additionally, increased pro-inflammatory cytokines and
decreased anti-inflammatory cytokines have been
demonstrated from lipopolysaccharide (LPS)-activated
microglia explanted from aged mice[26], suggesting the
abnormal immune state of microglia in the aged brain.
All of the above evidence suggests that the inflammatory
state of microglia in the aged brain primes them it to be
over-responsive to small stimuli that are otherwise well
controlled in the young brain. Eventually, the activation
of microglia in the aged brain loses control. It is still
uncertain what triggers the microglial activation in the
healthy aged brain; whether it is caused by degenerating
neurons or by abnormal protein aggregation found in
clinically normal elders is still unknown[22].
Microglia activation in the CNS: more blessing
than curse?
In the past decade there have been discussions on
whether microglia activation is beneficial or detrimental
to neurons. Most of the debate has arisen from in vitro
studies [27-30], which usually give ambiguous effects of
microglia on cultured neurons. These studies indicate
that microglia are capable of being both neurotrophic
and neurotoxic, depending on the specific stimulus, the
severity of injury, and the environment [31-34]. How-
ever, exactly under what scenario activated microglia are
neuroprotective or neurotoxic and what promotes trans-
formation between the two remains unknown. Microglia
are distributed ubiquitously throughout the brain and
function as resident macrophages and antigen-presenting
cells in the CNS[35,36]. They play vital roles in support-
ing and maintaining neuronal function, health, homeos-
tasis, and survival in both normal and pathological
microenvironment by phagocytosis of potentially deleter-
ious debris and secretion of neurotrophic factors to pro-
mote tissue repair. By using in vivo two-photon imaging
techniques, Nimmerjahn et al[37]. found that in the
healthy, intact brain microglia are actually highly active
and survey their microenvironment continually with
extremely motile processes and protrusions. The same
study also suggests that activated microglia exert a neu-
roprotective role by shielding the injured sites and pha-
gocytosing damaged tissue. Since microdamages may
happen frequently throughout the CNS due to microis-
chemic events or accumulated metabolic products, or
even degenerating neurons, it is conceivable that micro-
glia are constantly activated and, in most cases, respond
to these microdamages in a neurotrophic fashion [37].
As the sentinel and essential cells of the CNS, micro-
glia are not supposed to be harmful to the neuron.
However, if the microglia activation in the brain over-
steps the threshold of tolerability, it might contribute to
pathology rather than have a sentinel or defensive role
[38]. This is probably why microglia activation is notor-
ious for being harmful in the brain. Even though con-
crete and valid proof of neuroprotection of the activated
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strong evidence demonstrating the neurotrophic work of
activated microglia. In axotomy of the optic nerve of
amphibians, a rapid microglia response is exhibited with
efficient clearance of myelin debris (which contains inhi-
biting molecules of axon growth) and finally successful
axonal regeneration[39]. Activated microglia can also
clear glutamate without evoking inflammatory mediators
after traumatic injury and thus reduce neurotoxicity[40].
Grafting of cultured microglial cells into the lesioned
spinal cord of adult rats enhances neurite outgrowth
[41]. Microglia have been demonstrated to protect neu-
rons against ischemia either by synthesis of tumor
necrosis factor[42] or by engulfment of harmful invading
neutrophil granulocytes[43]. The protective roles of acti-
vated microglia have also been extensively discussed in
multiple sclerosis[44]. All of the above studies provide
strong evidence that activated microglial cells help
injured neurons recover and that microglia is strongly
indicated as beneficial to neuron survival. Therefore,
activation of microglia is generally more beneficial than
detrimental if the microglia is working normally. How-
ever, under conditions when microglia are deregulated,
their over-activation could be neurotoxic, which could
eventually contribute to neurodegeneration.
Distinct microglia in the aged brain: is it due to
so-called microglia senescence?
In contrast to acute CNS injuries, neurodegeneration as
in AD and PD is a chronic process that may take dec-
ades to develop. In this slowly progressive procedure,
activated microglia has been demonstrated to play
important detrimental roles [45-47]. This is opposite to
the physiological neuroprotective function of microglia
in the young brain. The destructive roles of the activated
microglia in the aged neurodegenerative brain may
result from age-associated microglia senescence, which
is similar to immunosenescence of macrophages, the
peripheral counterpart of microglia. Microglia senes-
cence renders microglia to function abnormally, to fail
to respond correctly to stimuli[48,49] and, eventually, to
promote neurodegeneration. The most prominent and
also the first identified feature of microglia senescence is
the morphological alteration described as “dystro-
phy.”[50] Characteristics of “dystrophic” microglia that
were observed in the aged brain include deramification
(loss of finely branched cytoplasmic processes), cytoplas-
mic beading/spheroid formation, shortened and twisted
cytoplasmic processes, and instances of partial or com-
plete cytoplasmic fragmentation[50]. Such dystrophic
microglia were prevalent and extensively distributed in
the brain of older human subjects[50,51], whereas nor-
mal ramified microglial morphology with only rare
instances of dystrophic microglia are seen in the young
brain[49] These observations provide initial evidence of
the age-associated changes in microglia in the healthy
elderly brain.
Apart from the dystrophic morphology, telomere
shortening has also been demonstrated in the aged
brain. Telomeres, the physical ends of eukaryotic chro-
mosomes, continually shorten with age and divide due
to the inability of DNA polymerase to completely repli-
cate linear DNA molecules. When cells eventually
exhaust their replicated potential, they enter replicative
senescence, leading to the substantial changes in cell
function and gene expression. Previous studies have
shown that telomere shortening, which is a sign of cell
senescence, occurs in rat microglia overtime in vitro
[ 5 2 ] ,a sw e l la si nv i v oi nr a tc e r e b e l l u ma n dc e r e b r a l
cortex with age[53]. Because microglia are the major
cell type that are capable of dividing to an appreciable
extent in the CNS, the reduction in brain telomere
length may be caused by telomere shortening in micro-
glia. More direct evidence in support of telomere short-
ening in microglia in the agedb r a i nc a m ef r o ms t u d i e s
of Flanary et al. who reported that microglial cells exhi-
bit significant telomere shortening and reduction of tel-
omerase activity during normal aging in rats[54].
Collectively, microglia in the aged brain is distinct from
that in the young brain both in morphology and in telo-
mere length, which indicate senescence. However, the
senescenced microglia are not universal in the aged
brain since scattered dystrophic microglia are usually
found alongside normal ramified microglial cells, sug-
gesting that only a subset of microglia become dys-
trophic, and not all of them are of the same age and
functional state[55]. It is possible that the number of
this subset increases with aging and ultimately outnum-
bers the neuroprotective normal-functional microglial
cells. These age-associated changes may underlie the
alterations of microglial function and their distinct
responses to injury.
Distinct pattern of microglia response to injury in
the aged brain
Microglia senescence is also manifested by their func-
tional alterations, such as altered inflammatory profile
[26,56], increased immunophenotypic expression[23],
and the switch from neuroprotective in the young brain
to neurotoxic in the aged brain when activated[48].
Microglia response to injury in the aged brain is distinct
when compared to that in the young adult brain regard-
ing the timing of microglia proliferation and presenta-
tion after the injury. For example, Conde et al. reported
that microglia proliferation in the aged rat brain was sig-
nificantly higher than in the young rat brain 4 days after
axotomy of the facial nerve[49]. Significant differences
in the activated microglia on the lesioned side were also
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senescence-accelerated prone mice (SAMP8) and senes-
cence-accelerated resistant mice (SAMR1), brain neutro-
phils and reactive astrocytes do not differ in number or
distribution between SAMP8 and SAMR1 mice, but
activated amoeboid microglia are distributed more
abundantly around and inside the hemorrhagic lesions
in old SAMP8 mice than in young SAMP8 mice[57].
The improvement of neurological deficits in old SAMP8
was also delayed, indicating the role of the distinct
microglia response in the delayed recovery. In a study of
intracerebral hemorrhage in young and aged rats, it was
o b s e r v e dt h a tm i c r o g l i aa c t i vation was significantly
h i g h e ri ny o u n gr a t st h a ni na g e do n e sw h e ne x a m i n e d
three days after hemorrhage [58]. The distinct pattern of
microglia response to injury in the aged brain has also
been recorded in the 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP)-induced neurotoxicity[59], the model
of controlled cortical impact (CCI)[60], cortical stab injury
[61], and transient retinal ischemia[62]. However, not all
studies reach consistent conclusions. For example, Hurley
and Coleman[63] did not find any age-related difference in
microglia response in either control or axotomized facial
nuclei. These inconsistent findings may be attributed to
the diversity of injury models, animal species, methods
regarding counting, and the definition of microglia activa-
tion. Taken together, it appears that microglia in the aged
brain respond to stimuli no less than that in the young
brain. The problem seems to be the changes of response
patterns and uncontrolled activation, which are the major
characters of microglia senescence.
Recent studies give more support to the hypothesis of
microglia senescence in the aged brain, which offers a
novel perspective on aging-related neurodegeneration by
looking at the neurodegenerative process from an alter-
native point of view. It appears that slow progressive neu-
rodegeneration and associated neuronal cell death may
result from impaired microglial cell function. This
hypothesis provides a potential therapeutic target of
improving microglia function by delaying microglia
senescence. However, before this proposal can be fully
accepted, there are still some key questions that need to
be answered. A critical, fundamental question is what is
the difference between “the activated microglia” and “the
aged microglia”. Even though Streit et al[64] gave a sug-
gestion in the difference between the two, describing that
“hypertrophy and retraction and thickening of process”
occurs in activation while “deramification, shortening
and twisting of processes, cytoplasmic fragmentation” are
features of aging, so far no definite biomarker or mor-
phology characters can distinguish the two with certainty.
The best way to indicate senescence versus activation is
to determine the dynamic activities of microglia and their
response to injury and whether they will ultimately
return to ramified resting state after stimuli and/or
whether the changes occur in a physiological environ-
ment free of stimuli. There are still many other questions
that are hard to answer so far. Is the activating state of
microglia in the aging brain co-existing with or secondary
to microglia dystrophy? As microglia are physiologically
multi-functional, which specific function of microglia is
primarily affected by microglia dystrophy? How is it
affected and what is the direct consequence of the
affected function? Is the deterioration of a specific micro-
glia function more related to neurodegeneration than
some other function? Clearly, much more research is
needed to answer these questions.
What factors cause microglia dysfunction in
aging brain?
An important question is whether there are any other
factors in addition to aging itself that could promote or
delay microglia dysfunction in the aged brain. Are the
age-related alterations in microglia function and mor-
phology resulting from intrinsic or extrinsic factors?
Does microglia over-activation and malfunction in the
aged brain come from their failure to respond correctly
to their microenvironment, or from an overloaded toxic
microenvironment? It has been demonstrated that
although the aged rodent and human myeloid dendritic
cells are poorly immunogenic, fully functional myeloid
dendritic cells can be generated in vitro from blood
monocytes from aged donors[9,65,66], suggesting that
there is no age-associated intrinsic defect in this lineage
and that the age-related changes in macrophage func-
tion may be reversible with the proper environment and
stimulation. Isolated microglia from aged brains exhibit
decreased process complexity, altered granularity, and
increased basal cytokines as compared to those from the
young brain, suggesting an elevated inflammatory state
in the aged microglia[56]. However, after being stimu-
lated with LPS, the fold-over-basal LPS response
remains constant across ages, indicating a comparable
inflammatory response machinery in aging microglia to
that of young ones[56]. These observations suggest that
microglia dysfunction in the aged brain might be more
related to the extrinsic events than intrinsic ones.
The notion that extrinsic rather than intrinsic factors
are the major determinants for microglia’sf u n c t i o ni s
also supported by the regional differences in microglia.
It has been shown that in different regions of the brain,
microglia activation shows differential phenotypes.
Ramified activated microglia are mainly associated with
periventricular region, whereas innate, amoeboid phago-
cytic phenotype of microglia is seen within the deep
subcortical region[67]. These observations further sug-
gest that different stimuli or environments induce differ-
ent morphology and functions of activated microglia.
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tive stress, neuroendocrine factors[10,68], hormones, and
pathological factors such as abnormal protein aggregation
[52] that exists in the microenvironment where microglia
live. For example, amyloid has been shown to accelerate
microglia senescence[52]. Thus, it is conceivable that tar-
geting the factors influencing microglia function in the
aged environment might restore at least part of the neuro-
protective function of microglia in the elderly.
While most evidence points to the importance of
extrinsic factors, there are alternative explanations of
microglia senescence and malfunction in the aged brain.
It has been suggested that microglia do not constitute a
single uniform cell population, but rather comprise a
family of cells with diverse phenotypes. Once activated,
they are committed to various phenotypes[38,40,69].
Whether it is possible to avoid the commitment to a
destructive phenotype or at least to change the commit-
ment, if the activation has already occurred, remains
unknown. There is also evidence implicating intrinsic
alterations as the cause of microglia senescence[70],
which is actually easier to accept since aging is generally
considered to be a natural course initiated by gene
alterations. The exact cause of microglia senescence and
malfunction in the aged brain clearly need further inves-
tigation, as it might provide key insight into the
mechanistic switch between neuroprotective function
and neurotoxicity of the cells.
Molecular basis of microglia dysfunction in the
aged brain
Little is known about the molecular basis of microglia
dysfunction in the aged brain. It may closely correlate to
and share the similar molecular mechanisms of general
aging, which is an extremely complex multifactorial pro-
cess including molecular, cellular, and systemic levels
and even the interactions among these three levels.
Many genes change expression with age. DNA microar-
rays have been used to determine genome-wide tran-
scriptional changes with age and allow researchers to
compile a transcriptional fingerprint of “normal” aging
and to compare it with that of neurodegeneration. This
approach enables the identification of gene expression
changes relevant to senescence and neurodegeneration.
In a study that screened 13,500 Drosophila genes in
young, old, and oxygen-stressed flies, Landis et al. found
upregulation of genes related to purine biosynthesis,
heat-shock proteins, antioxidants, and innate immune
responses in old flies and in oxygen-stressed flies, sug-
gesting the specific gene expression profile during aging
[71]. Insulin-like signaling pathway has been shown to
regulate life span in worms, flies, and mice[72].
In the mouse hippocampus, the basal expression of
128 genes changes with aging[73]. The genes whose
expression is increased in the aged mouse hippocampus
include the MHC TL region, thymic shared antigen
(TSA-1), cytokine (IL-1b), TNF-a, and chemokine
(MCP-1), suggesting that expression of the immune-
related genes changes with aging in the brain. In an
established mouse model of AD (PS1-APP mice), altered
expression of many genes was seen in microglia from
old mice, but not from younger ones, when compared
with their littermate controls. These genes include Ab-
binding scavenger receptors A (SRA), CD36, receptor
for advanced glycosylation end products (RAGE), Ab-
degrading enzymes (insulysin, neprilysin) and MMP9
[74]. An altered gene expression profile has also been
seen in microglia from AD brain. Walker et al[70]
demonstrated that when compared with those from
non-demented brains, large alterations in gene tran-
scription were found in microglia derived from postmor-
tem AD brain, including upregulation of many
proinflammatory cytokines and chemokines such as IL-
1b, IL-8, and matrix metalloproteinases (MMP). Deregu-
lation of these genes might underlie the mechanisms of
microglia dysfunction in the aged brain and in
neurodegeneration.
Role of microglia in Parkinson’s disease and
Alzheimer’s disease
The considerable contribution of microglia activation to
the pathogenesis of PD has long been proposed
[45,46,75]. Aging is the strongest risk factor for PD,
which is true not only in the epidemiological studies,
but also in the models of PD. A low systemic dose of
r o t e n o n eh a dn oe f f e c to ny o u n gr a t s ,b u tl e dt oa2 0 -
30% reduction of dopaminergic neurons in the substan-
tia nigra of older rats[76]. Similar phenomena replicate
in MPTP-induced dopaminergic neuronal loss in elderly
mice, in which more severe and persistent microglia
activation associated with TH neuronal loss was found
in MPTP-treated elderly rodents[77], suggesting that
age-associated microglia over-activation may contribute
to the increased sensitivity of dopaminergic neurons to
neurotoxins. A recent study demonstrated that whether
microglia are neuroprotective or neurotoxic to dopami-
nergic neurons is age-dependent[48], in which activated
microglia switches from neuroprotective in the neonatal
brain to neurotoxic in the aged brain. It appears that
aging could be the determining factor of microglial
functions. In other words, microglia senescence that
occurs in the aged brain is responsible for the functional
alterations and dysregulated responses of microglia. In
the aged human brain, a significantly greater area of the
substantia nigra is occupied by microglial cell bodies
and processes than that of younger subjects[78]. More-
over, the dopaminergic neurons are more sensitive to
oxidative stress imposed by microglia than other types
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and/or senescenced microglia in the aged brain has put
the dopaminergic neurons in a more dangerous environ-
ment than that of the young brain. We, therefore, pro-
pose that in PD microglial function changes with age by
releasing more inflammatory cytokines or oxidative
stress, which prime microglia in the substantia nigra to
be in an activating state and cause a dysregulated micro-
glia response to pathogenic stimuli from the environ-
ment. Under this scenario, previously neurotrophic
microglia turn into neurotoxic and release less-con-
trolled oxidative products and overproduce inflamma-
tory cytokines, which eventually promotes or leads to
dopaminergic neurodegeneration (Figure 1). The similar
scenario may also occur in AD, another notable age-
related neurodegenerative disease, in which microglia
has also been considered to be a major player in its
pathogenesis. Microglia over-activation and dysfunction
are seen in AD brain. Clustering of microglia are usually
found around the senile plaques in the aged non-
demented and AD brain[22]. Aging microglia are more
prevalent in AD brain than age-matched, non-demented
brain[54]. Active microglial cells are needed as scaven-
ger cells in the CNS. However, both compromised amy-
loid-clearing ability of microglia[80] and the damage of
microglia by amyloid[81] have been reported in AD
brain. By not responding to normal regulatory feedback
mechanisms and/or having an impairment in their abil-
ity to clear Ab, microglia cells lose their ability to handle
potentially toxic compounds and become cytotoxic due
to their persistent activation[77]. Thus, Bernhardi et al.
proposed that AD is not caused by hyperactive but
rather by dysfunctional microglia[82]. In a recent study,
Streit et al. found dystrophic (fragmented) rather than
activated microglial cells are colocalized invariably with
degenerating neuronal structures positive for tau (neuro-
pil threads, neurofibrillary tangles, neuritic plaques) in
the brains with AD pathologies[83]. The microglial dys-
trophy even precedes the spread of tau pathology. these
observations support the idea that microglia senescence
rather than microglia activation contributes to the
pathogenesis of AD. Further investigation of microglia
Figure 1 Age-primed microglia hypothesis of Parkinson’s disease. Microglia functions differentially in the substantia nigra of the young (left)
and aged (right) brain. Left: When facing pathogenic stimuli (large black dots), the healthy microglia in the young brain respond by releasing
neurotrophic factors (small yellow dots) to support the endangered dopaminergic neurons and limit neuronal damages. Right: In the aged brain
the microglia are primed with aging and function abnormally. When exposed to pathogenic stimuli, they are overactivated and release excessive
oxidative stress and inflammatory factors (small black dots), which damage the vulnerable dopaminergic neurons and eventually lead to
neurodegeneration.
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in probing the microglia biology and thus a new thera-
peutic direction in preventing and treating AD.
Conclusion remarks
Aging is an extremely complex, multifactorial process
with deregulation of the immune system. A wide spec-
trum of changes occurs in both adaptive and innate
immune systems, particularly in the myeloid lineage,
including the microglia, in the aged brain. Many neuro-
degenerative diseases are age-related, and the neuroin-
flammation characteristic of chronic reactive
microgliosis is thought to contribute to the age-related
neurodegeneration. Due to the original sentinel role and
being essential cells of the brain, microglia can hardly
evolve to threaten the neuron. Much evidence has
emerged to suggest the neuroprotective effect of micro-
glia under specific circumstances. The traditional view
of the detrimental activated microglia needs to be reap-
praised. An alternative new hypothesis of microglia
senescence has been proposed, which gives novel view-
points on this issue. Whether microglia dysfunction is
determined by their intrinsic changes or results from a
response to altered environment in the aging process
remains controversial. Whether microglia activation is a
curse or blessing appears to be dependent on the timing,
the environment, and the nature of the stimuli. More
studies are needed for further understanding of the
detailed regulation of microglia activation and microglia
senescence during aging and the mechanism of micro-
glia over-activation under specific neurodegenerative
conditions. Revealing the molecular mechanisms of
microglia dysfunction in neurodegeneration will help
develop therapeutic strategies for treating aging-related
neurodegenerative diseases.
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